Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) CEO Discusses Preventative Measures to Reduce Risk of Data Leaks on “Weekly Hack” Segment

 

• During the first three quarters of 2023, 32.23 million data breaches were exposed worldwide
• Sekur CEO Alain Ghiai’s “Weekly Hack” segment explores preventative measures to lessen the likelihood of an attack or data leak
• The company’s Swiss-hosted solutions offer individuals, businesses, and governments options for secure and private communications and internet security

During the pandemic, data breaches worldwide spiraled out of control, with 284.34 million breaches in data recorded. Since then, the highest recorded data breach numbers came during the first three quarters of 2023, with 32.25 million data breaches exposed worldwide (https://ibn.fm/ZXWWU). This week’s “Sekur Privacy & Sekur Security – The Weekly Hack” segment with TV host and multi-media journalist Ana Berry and internationally acclaimed internet privacy expert Mr. Alain Ghiai, CEO of Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, explores preventative measures that can lessen the likelihood of an attack or data leak.

Mr. Ghiai recommends never using free WiFi services and not using free Big Tech emails and messaging services when transmitting secure and private information. He also recommends using safe and encrypted VPN services to ensure private data isn’t hijacked (https://ibn.fm/gV5Zi). To help users with a secure means of communicating and transmitting secure data – Sekur’s suite of cybersecurity and internet privacy solutions provides users with the highest level of security with the company’s wholly owned and managed Swiss-hosted solutions.

Sekur’s suite of services includes:

SekurMail(R) with SekurSend/SekurReply is an encrypted email service offering a private, safe, and powerful tool to communicate with everyone within or outside the Sekur ecosystem. SekurMail protects personal information and communications from being accessed by unauthorized parties.

SekurVPN(R) creates a secure, encrypted connection between client’s devices and the internet, giving safe access to the web by routing connections through the company’s wholly-owned Swiss servers. All data sent and received is hidden from prying eyes, including the client’s Internet Service Provider, potential hackers, government surveillance agencies, and more.

SekurMessenger(R) is a Swiss-hosted private and secure messaging communications app that provides secure and private chat, self-deleting chat, voice recording, and file transfer via any mobile device, tablet, or desktop computer. The app is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged.

Sekur has chosen Switzerland to locate its data storage because of its neutrality, independence, strong privacy laws, long-standing political stability, and excellent international relations. All data is stored in bank-approved, state-of-the-art ISO-certified data centers – with data protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offers some of the strongest privacy protection in the world for both individuals and organizations.

Sekur makes its services available to individuals, businesses, and governments worldwide. None of the data protected by the company is ever sold to third-party companies or tracked. (The suite is available as a subscription service, and during the “Weekly Hack” segment, Mr. Ghiai offers a 15% savings good for five years with PROMO CODE: PRIVACY).

For more information, visit the company’s website at www.SekurPrivateData.com, or the company’s product site at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap

 

• Lexaria, a global innovator in drug delivery platforms, has laid down its GLP-1 human and animal studies roadmap for the 2024 calendar year
• This builds on the success of its human pilot study, which marked a successful undertaking for exploring its patented DehydraTECH(TM) technology for the improved delivery of the GLP-1 drug semaglutide, available commercially in the branded product Rybelsus(R)
• The company’s chronic dosing animal study and its second human pilot study will commence in Spring and run for 12 weeks. The third human pilot study will start in May or June
• These studies will evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced five additional studies that aim to support commercial partnering for glucagon-like peptide-1 (“GLP-1”) agonists with its patented DehydraTECH(TM) technology. This follows the update on the final results from its human pilot study in what marked a successful undertaking for exploring DehydraTECH for the improved delivery of the GLP-1 drug Rybelsus(R), reduced side effects, enhanced weight loss, and improved health outcomes, per recent Zacks report (https://ibn.fm/CzDhY).

Of note from the human pilot study was the sustained higher levels of semaglutide in blood using DehydraTECH technology, even 24 hours after a single dose.  DehydraTECH processing technology enhancements also achieved better blood glucose control, faster peak drug delivery and reduced side effects.

The 2024 GLP-1 study program will aim to characterize the pharmacokinetics of DehydraTECH processing technology enhancements while also exploring the commercial applicability of DehydraTECH-formulated versions of semaglutide, liraglutide, and tirzepatide. Lexaria plans to embark on one animal, three human studies, and long-term stability testing on DehydraTECH compositions of GLP-1 agonists. All of these proposed studies will depend upon sufficient funding, and all human studies will be investigator initiated non-registrational studies, and will require certain approvals before they commence.

Lexaria’s chronic dosing animal study will advance 12 arms with 8-10 obese rats per arm. It is scheduled to commence in Spring 2024. It will run for 12 weeks, with the primary objective of evaluating weight loss, pharmacokinetics, and blood sugar control over the duration of the study. Once completed, a full analysis will be performed, and results will be shared with stakeholders. This study will use DehydraTECH formulations of semaglutide and liraglutide alone and with DehydraTECH-CBD.

A second human pilot study will begin in Spring 2024, with the third starting in May or June 2024. The latter will enroll up to eight healthy human volunteers and evaluate DehydraTECH’s effectiveness in combination with a dual-action GLP-1 agonist and a glucose-dependent insulintropic peptide (“GIP”) drug absent in the SNAC formulation. It will build on the second human clinical study, whose primary objective would be to evaluate tolerability, side effects, pharmacokinetics, and blood sugar control.

For the 2024 calendar year, Lexaria also plans to evaluate the chemical and microbiological purity and stability of select DehydraTECH compositions over 6-12 months. This long term stability testing is crucial if oral variants of GLP-1 drugs are to be seriously considered as replacements for currently injectable versions of these drugs. All the studies lined up for the year will support this objective, and the company’s management is optimistic that it will be realized.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

Astiva Health CEO Dr. Tri Nguyen Discusses Company’s Growth and Vision on The Bell2Bell Podcast

 In a recent episode of the ‘Bell2Bell Podcast’ hosted by Stuart Smith, Astiva Health was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector. The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO, Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology.

Listen to the full interview to hear Dr. Nguyen discuss Astiva Health’s journey since its inception in 2020 and its expansion plans. He shared insightful details about the company’s expansion to Los Angeles, San Bernardino, and Riverside from January 1, 2024, marking a pivotal phase in transforming healthcare delivery.

One key highlight from the podcast was Astiva Health surpassing the 10,000-member milestone. Dr. Nguyen attributed this success to the company’s philosophy, which emphasizes loving life at any age. This principle is central to Astiva’s commitment to ensuring life is lived with fulfillment.

Astiva Health’s approach goes beyond providing medical care and prescription drugs. As Dr. Nguyen explains in the interview, it includes offering rich supplemental benefits to engage enrollees in a meaningful, healthy life. He emphasized the importance of patient involvement in successful medical outcomes, a cornerstone of Astiva Health’s strategy.

Looking forward in the podcast discussion, Dr. Nguyen outlined Astiva Health’s operational goals for 2024, including an ambitious plan to list its common shares on the NASDAQ Global Select. This strategic move aligns with Astiva Health’s broader goals of expanding its impact.

The vision for Astiva Health, as Dr. Nguyen shares on the Bell2Bell Podcast, is to redefine healthcare accessibility and quality. He envisions Astiva Health as a comprehensive healthcare provider for all who can benefit from it, highlighting potential growth and service expansion.

The interview concluded with Dr. Nguyen thanking Stuart Smith for the opportunity to discuss Astiva Health’s journey and future plans. For more information about Astiva Health, listeners are directed to the company’s website.

Catch the full depth of this engaging conversation with Dr. Tri Nguyen on the Bell2Bell Podcast, offering listeners a deeper understanding of Astiva Health’s mission, achievements, and future aspirations in the healthcare sector.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN